Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PyramIDH: Ivosidenib vs azacitidine monotherapy in HMA-naive IDH1-mutated MDS
jRCT2051240209Phase 3Recruiting
- Sponsor
- Servier
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in myelodysplastic syndrome (MDS) comparing Ivosidenib monotherapy with Azacitidine monotherapy (2 arms). Primary endpoint: Complete response + partial response rate at 4 months. Started Dec 2024; status: recruiting.
02
Drugs
ivosidenibazacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2051240209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240209.